Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSA meta-analysis of four trials and 655 patients found CGRP monoclonal antibodies cut cluster headache attacks by 0.81 per week, an effect too small and too uncertain to call, with a placebo response between 27 and 53 percent doing much of the work.
A target trial emulation of 161,798 obese, nondiabetic adults found GLP-1 users had a hazard ratio of 0.59 for obesity-associated cancers, about 41 percent fewer diagnoses. The protection held in every subgroup but one.
Petrelintide's full Phase 2 data landed at the diabetes meeting. The weight loss trailed the incretins, but vomiting came in below the placebo arm, which is the whole case for the amylin class.
In 13,204 matched pairs of adults with obesity and an autoimmune disease, GLP-1 use was tied to about 31 percent fewer pulmonary embolisms, fewer deep-vein clots and strokes, and nearly half the death rate. Heart attacks and coronary stents, the arterial outcomes, did not move, so the benefit clustered where these patients are already primed to clot.
TRANSCEND-T2D-1, published in The Lancet and presented at ADA on Saturday, showed retatrutide cutting A1C by up to 2.0 points and pushing as many as 46 percent of adults with type 2 diabetes back to a normal, non-diabetic blood-sugar level. The same dataset logged seven arrhythmias and three major cardiac events across 403 drug-treated patients versus none on placebo. The counts are too small to settle anything, but retatrutide's glucagon-receptor arm is the obvious mechanism, and the cardiovascular outcomes trial does not read out until 2027.
In 740 emergency stroke patients, the 41 on a GLP-1 developed aspiration pneumonia at 26.8 percent versus 10.3 percent, a matched odds ratio of 3.25. Brain bleeding and 90-day disability did not differ, so the fix is airway protection, not skipping the thrombectomy.
A pharmacovigilance analysis of 1,618 thrombotic reports filed against GLP-1 drugs from 2020 to 2025 found no excess clotting signal. Reports ran about a third below the rate for an average drug, and lower than orlistat or SGLT2 inhibitors. Voluntary reports cannot prove cause, but the feared alarm did not sound.
A matched study of 18,062 adults over 50 found GLP-1 users had about 85 percent fewer major fractures, plus less osteoporosis and arthritis, than people on other weight-loss drugs. The comparison is relative and observational, but the bone-fragility fear did not show up in the data.
A new subgroup analysis of the FLOW trial split its diabetic kidney-disease patients by cardiovascular status. Semaglutide cut the combined kidney-and-death risk by a similar amount whether patients had clogged arteries, heart failure, or no diagnosed heart disease at all, and every test for a difference came back null. The heart-failure group, usually the hardest to help, needed the fewest patients treated to prevent one kidney event.
Peptide receptor radionuclide therapy won its approval in midgut neuroendocrine tumors. A single-center decade of records in 34 patients with the under-studied foregut and hindgut tumors found an 80 percent disease-control rate, median progression-free survival of 29.7 months, and more than half alive at five years, with serious side effects in only 5 of 34.
A 111,646-woman records study found GLP-1 users were diagnosed with breast cancer roughly a third less often. Propensity matching on BMI, breast density, and diabetes barely moved the estimate, from 0.65 to 0.70.
In 12 people with no pancreas, infused GLP-1 cut post-meal glucose 45 percent and slowed gastric emptying, while GIP left glucose untouched but cut bone breakdown 65 percent and raised heart rate. The two incretins behind tirzepatide run separate programs outside the pancreas.
A disproportionality analysis of 3,460 biliary adverse-event reports across five GLP-1 receptor agonists, with semaglutide as the within-class reference, found dulaglutide's cholangitis signal at PRR 1.65, exenatide topping cholelithiasis at 1.33, and meaningful heterogeneity across the class. The standard class-warning summary does not capture it.
A TriNetX cohort published in the Journal of Clinical Neuroscience matched 261 GLP-1-exposed adults to 261 unexposed controls, all of whom underwent endovascular thrombectomy for acute ischemic stroke, and tracked three-year mortality (11.5 vs 29.9 percent, HR 0.334, 95% CI 0.219-0.508) and inpatient hospitalizations (39.8 vs 54.8 percent, HR 0.514, 95% CI 0.398-0.663). The class-level exposure flag means the signal applies to GLP-1 receptor agonists as a class, not to any one molecule.
A 13-trial network meta-analysis of 12 MASLD drugs at fibrosis stages F1-F3 ranked survodutide 6 mg/week at SUCRA 92.0 percent, with a relative risk of 7.25 for NASH resolution without fibrosis worsening versus placebo (95% CI 2.07 to 25.36). Tirzepatide 15 mg landed second. Resmetirom, the first FDA-approved MASH drug, sat at the bottom of the active interventions.